Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Raises Price Target to $90
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Vikram Purohit maintains an Equal-Weight rating on Axsome Therapeutics (NASDAQ:AXSM) and raises the price target from $87 to $90.
June 12, 2023 | 1:31 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Morgan Stanley maintains an Equal-Weight rating on Axsome Therapeutics and raises the price target from $87 to $90.
Morgan Stanley's decision to maintain an Equal-Weight rating on Axsome Therapeutics indicates a neutral outlook for the stock. The price target increase from $87 to $90 suggests a slightly more optimistic view, but overall, the impact on the stock price is expected to be neutral in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100